HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
HUTCHMED to hold a conference call at 8:00 am EDT / 1:00 pm BST /…
News
Intellabridge Technology Corporation Announces the Appointment of Lee Fan to the Board of Directors and the Resignation of Jack Donenfeld
Menlo Park, California, Vancouver, British Columbia, and Boulder, Colorado–(Newsfile Corp. – May 2, 2022) –…
The Executive Talk by ShareInvestor: Thonburi Healthcare Group PCL (SET: THG)
BANGKOK, May 2, 2022 – (ACN Newswire) – Thonburi Healthcare Group PCL (SET: THG) Chief…
BlackRock Capital Investment Corporation Reports Financial Results for the Quarter Ended March 31, 2022, Declares Quarterly Cash Distribution of $0.10 per Share
GAAP Net Investment Income (“GAAP NII”) was $6.5 million, or $0.09 per share, up 9%…
Energous Adds Three Industry Veterans to Board of Advisors as Company Focuses on Powering the Growing Industrial and Retail Internet of Things Ecosystem
Additions of Bob Friday, Alessandro Piovaccari and Mark Tyndall will support Energous as it continues…
Argonne Plays Key Role in Advancing Hydrogen for Clean Energy
LEMONT, Ill.–(BUSINESS WIRE)–Producing hydrogen from zero- or low-carbon energy sources holds enormous potential for its…
Enterprise Reports First Quarter 2022 Earnings
HOUSTON–(BUSINESS WIRE)–Enterprise Products Partners L.P. (“Enterprise”) (NYSE: EPD) today announced its financial results for the…
TrustSwap’s Team.Finance Continues to Be the Industry Leader in Cryptocurrency Token Locks and Management
LOS ANGELES–(BUSINESS WIRE)–$SWAP #blockchain–The team at TrustSwap recently released a detailed comparison of its Team.Finance…
Nicox at ARVO 2022: Presentation of clinical Phase 2 results on NCX 4251 and new non-clinical evidence of improved hemodynamic and retinal cell physiology on NCX 470
Press Release Nicox at ARVO 2022: Presentation of clinical Phase 2 results on NCX 4251…
OSE Immunotherapeutics Announces New European Patent Granted Covering CLEC-1, Novel Myeloid Immune Checkpoint Target For Cancer Immunotherapy
A new protection covering CLEC-1 antagonists until 2037 Patent also granted in Japan and notice…
ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland…
Idorsia’s new treatment QUVIVIQ (daridorexant) is now available in the US for adults living with insomnia
In the US, QUVIVIQ™ (daridorexant) CIV 25 mg and 50 mg tablets are indicated for…
Hilti Transforms Supply Chain Planning with Blue Yonder
Global company implemented Blue Yonder’s S&OP solution to enhance its integrated business planning process, improving…
Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
REDWOOD CITY, Calif., May 01, 2022 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage…
C3.AI 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess Of $100,000 of Deadline in Class Action Lawsuit Against C3.ai, Inc. – AI
NEW ORLEANS, La.–(BUSINESS WIRE)–ClaimsFiler, a FREE shareholder information service, reminds investors that they have only…
First Internet Bancorp Announces Termination of First Century Merger Agreement
FISHERS, Ind.–(BUSINESS WIRE)–First Internet Bancorp (the “Company”) (Nasdaq: INBK), the parent company of First Internet…
Adverum Biotechnologies Presents Additional Efficacy and Safety Data from the OPTIC Trial of ADVM-022 in Wet AMD at the ARVO 2022 Annual Meeting
– Poster highlights analysis of baseline neutralizing antibodies to AAV.7m8 and impact on ADVM-022 efficacy…
Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism
Results Presented Today at the Pediatric Endocrine Society’s 2022 Annual Meeting Highly significant ~75% reduction…
Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting
— Data Demonstrate Rapid and Complete Wound Healing, with Six of Eight (75%) Patients Achieving…
Ascendis Pharma A/S to Present New Endocrinology Results at Four Medical Meetings in May
New data highlights include: – Phase 3 open-label extension study data for growth hormone-deficient children treated…